NCT03709082 2024-03-05Palbociclib in Estrogen Receptor Positive (ER+) Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast CancerUniversity of Kansas Medical CenterPhase 1/2 Terminated3 enrolled
NCT02657343 2022-08-01An Open-Label, Phase Ib/II Clinical Trial Of Cdk 4/6 Inhibitor, Ribociclib (Lee011), In Combination With Trastuzumab Or T-Dm1 For Advanced/Metastatic Her2-Positive Breast Cancer.Dana-Farber Cancer InstitutePhase 1/2 Completed25 enrolled 16 charts
NCT02318901 2019-10-21PembroMabWestern Regional Medical CenterPhase 1/2 Terminated16 enrolled 6 charts
NCT02658084 2019-04-17Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast CancerUniversity of MiamiPhase 1/2 Terminated2 enrolled 7 charts